Compare AbCellera Biologics Inc (ABCL) vs VanEck Australian Floating Rate ETF (FLOT) Price & Performance

AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.

The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.

FLOT trades at $50.96, up 0.08% on the day, with a bearish technical signal from moving averages and oscillators showing neutral momentum. The ETF focuses on high-quality floating rate bonds, offering a 4.0% SEC yield, and recent dividends include $0.18 paid in June 2026. News highlights potential Fed rate hikes as a catalyst for yield growth, while credit quality remains strong with minimal default risk.

Outlook is cautious due to bearish technicals and interest rate uncertainty, but FLOT provides a stable income stream with low credit risk. Key risks include inflation-driven rate volatility and economic shifts affecting bond yields, making it suitable for investors seeking short-term cash parking with modest returns above Treasuries.